Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • steroid-refractory
Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis
Posted inGastroenterology Specialties

Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis

Posted by MedXY By MedXY 08/17/2025
Cyclosporin demonstrated high clinical response rates in adults with severe steroid-refractory ulcerative colitis, allowing over half to avoid colectomy and highlighting its role as an effective rescue therapy.
Read More
Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial
Posted inClinical Updates news Specialties Transplantation

Ruxolitinib Offers Durable Clinical Benefit in Steroid-Refractory Chronic Graft-Versus-Host Disease: Three-Year Final Results of the REACH3 Trial

Posted by MedXY By MedXY 08/07/2025
The REACH3 study confirms ruxolitinib's superiority over best available therapy in steroid-refractory/dependent chronic GVHD, demonstrating sustained efficacy, improved failure-free survival, and a manageable long-term safety profile over three years.
Read More
  • Impaired Sleep Homeostasis and Respiratory Instability: Identifying Novel Biomarkers for Sudden Unexpected Death in Epilepsy
  • Remote Expertise, Local Impact: Telemedicine Models Outperform Onboard Care in Mobile Stroke Units
  • Bridging the Care Gap: Smartphone-Based Pulmonary Rehabilitation Enhances Quality of Life and Physical Activity in Chronic Respiratory Disease
  • Individualized Feedback Letters Fail to Reduce Long-Term Alcohol Consumption: Insights from a 4-Year RCT
  • Rule-Based Chatbots Outperform LLMs in Depressive Symptom Management: A Systematic Review and Meta-Analysis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening SGLT2 inhibitors targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in